Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.40 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.40 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.37 |
| ▸ | ESR1 | P03372 | 1/20 | 0.36 |
| ▸ | ESRRG | P62508 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6437358 | 0.80 | GAA (0.47) | GAAPDE3BPDE3AP2RY12ALDH1A1 | |
| SCHEMBL6968933 | 0.80 | DRD2 (0.53) | GAAALDH1A1 | |
| SCHEMBL14844426 | 0.80 | LTA4H (0.53) | GAAESR1ESRRG | |
| SCHEMBL27559192 | 0.79 | GAA (0.46) | GAAPDE3BPDE3AP2RY12ALDH3A1 | |
| SCHEMBL7501215 | 0.79 | KCNA3 (0.62) | GAABACE1KCNA3ALDH1A1 | |
| SCHEMBL14844393 | 0.78 | GAA (0.46) | GAAPDE3BPDE3AP2RY12ALDH3A1 | |
| SCHEMBL11767977 | 0.78 | GAA (0.68) | GAAALDH3A1KCNA3HRH3MAPT | |
| SCHEMBL7771160 | 0.77 | HRH3 (0.49) | GAAPDE3BPDE3AP2RY12BACE1 | |
| SCHEMBL29359699 | 0.77 | LSS (0.54) | BACE1KCNA3HRH3 | |
| SCHEMBL3472112 | 0.77 | SYK (0.43) | GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040110665-A1 | Desleucyl glycopeptide antibiotics and methods of making same | KAHNE DANIEL (US) | 2004-06-10 | — | — | US | disclosed |
| US-6699836-B2 | Vancomycin analogs | THE TRUSTEES OF PRINCETON UNIVERSITY | 2004-03-02 | — | — | US | disclosed |
| EP-0667353-B1 | Glycopeptide antibiotic derivatives | LILLY CO ELI (US) | 2003-10-29 | — | — | EP | disclosed |
| EP-0848004-B1 | PYRROLIDINE DERIVATIVES HAVING PHOSPHOLIPASE A2 INHIBITORY ACTIVITY | SHIONOGI & CO (JP) | 2003-04-02 | — | — | EP | disclosed |
| US-6518243-B1 | Desleucyl glycopeptide antibiotics and methods of making same | TRUSTEES OF PRINCETON UNIVERSITY | 2003-02-11 | — | — | US | disclosed |
| US-20020042365-A1 | Vancomycin analogs | TRUSTEES OF PRINCETON UNIVERSITY, THE | 2002-04-11 | — | — | US | disclosed |
| EP-1016670-A1 | Glycopeptide antibiotic derivatives | ELI LILLY AND COMPANY (US) | 2000-07-05 | — | — | EP | disclosed |
| US-5977062-A | ACTIVE AGAINST ANTIBIOTIC RESISTANT BACTERIA | ELI LILLY AND COMPANY (US) | 1999-11-02 | — | — | US | disclosed |
| US-5955616-A | PROSTAGLANDIN INHIBITORS | SHIONOGI & CO., LTD. (JP) | 1999-09-21 | — | — | US | disclosed |
| EP-0848004-A1 | PYRROLIDINE DERIVATIVES HAVING PHOSPHOLIPASE A2 INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 1998-06-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110665-A1 | Desleucyl glycopeptide antibiotics and methods of making same | FUT6, FUT5, ST6GAL1 | GAA 165/4885PDE3B 2431/4885PDE3A 2580/4885 |
| US-20020042365-A1 | Vancomycin analogs | VNN1, PTMS, ASNS | GAA 735/4885PDE3B 4447/4885PDE3A 4311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.